Safety of Transcranial Direct Current Stimulation in the Subacute Phase After Stroke (NEUROSTIM)
Stroke is the second cause of death worldwide and represented the first cause of death in Brazil between 2006 and 2010. Most patients survive, and there is a need to develop cost-effective rehabilitation strategies to decrease the burden of disability from stroke.
This study addresses this important issue, by evaluating, in the early phase post-stroke, effects of motor conventional physical therapy associated or not with transcranial direct current stimulation (tDCS).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The investigators main goal is to confirm the safety of transcranial direct current stimulation (tDCS) associated with conventional physical therapy, compared to conventional physical therapy associated with sham tDCS, for upper limb rehabilitation in an early phase (72 hours until 6 weeks) after stroke. Patients will be randomized to receive one of these two treatments, 3 times per week, for 2 weeks. Adverse effects will be monitored during each session. The working hypothesis is that conventional physical therapy associated with active tDCS in the subacute phase of ischemic stroke will be as safe as conventional therapy alone. The investigators will also preliminarily evaluate the efficacy of active tDCS associated with conventional therapy, compared to conventional therapy alone, in improvement of upper limb motor impairment. The investigators secondary goals are: 1) To compare effects of the above mentioned interventions on disability, spasticity and quality of life, in patients at an early stage after stroke ( subacute phase), immediately after treatment and 3 months later. The investigators hypothesis is that the association of conventional physical therapy and active tDCS will lead to better outcomes than conventional therapy alone. Patients will be assessed before the first session and after the last session of treatment, as well as 3 months after the last session of treatment.
Preliminary data about structural and functional connectivity will be collected in order to plan future studies related to mechanisms of tDCS in the subacute phase after stroke.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Sao Paulo, Brasil, 05652-901
- Danielle Boasquevisque
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Ischemic stroke confirmed by computed tomography or magnetic resonance imaging, with onset between 72 hours and 6 weeks before enrollment.
- Unilateral paresis of upper limb
- National Institute of Health Stroke Scale ( NIHSS) score of at least 1 point in items 5a or 5b .
- Ability to provide written informed consent (patient ou legal representative).
Exclusion Criteria:
- Lesions affecting the corticomotor pathway in the hemisphere contralateral to the stroke.
- Neurologic diseases except migraine.
- Modified Rankin Scale > 2 prior to stroke.
- Advanced systemic disease such as cancer or advanced chronic renal disease.
- Clinical instability such as uncontrolled cardiac arrhythmia or heart failure.
- Contraindication for physical therapy.
- Pregnancy.
- Absolute or relative contraindications to tDCS: metallic prosthesis in the head or neck; lesions on the scalp, history of neurosurgery, pacemaker.
- Comprehension aphasia
- Dementia
- Cerebellar stroke or ataxia caused by involvement of cerebellar pathways in the brainstem
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Active tDCS+ Physical Therapy
Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes.
After active session of tDCS, the patient will receive physical therapy for 60 minutes.
Number of treatment sessions: 6 (3 times a week, for 2 weeks)
|
Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Physical therapy will be administered for 60 minutes
|
|
Comparador Falso: Sham tDCS+Physical Therapy
Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks) |
In sham tDCS, no current will be delivered through the tDCS device.
Physical therapy will be administered for 60 minutes
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety of the intervention as assessed by frequency of adverse events
Prazo: 2 weeks
|
frequency of adverse events in the active and sham arms
|
2 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Improvement post treatment as measured by the Modified Rankin Scale
Prazo: 2 weeks and 14 weeks
|
Improvement post treatment
|
2 weeks and 14 weeks
|
|
Improvement post treatment as measured by the NIH Stroke Scale
Prazo: 2 weeks and 14 weeks
|
Improvement post treatment
|
2 weeks and 14 weeks
|
|
Improvement post treatment as measured by the Stroke Impact Scale
Prazo: 2 weeks and 14 weeks
|
Improvement post treatment
|
2 weeks and 14 weeks
|
|
Upper limb subscale of Fugl Meyer Assessment of Sensorimotor recovery after stroke
Prazo: 2 weeks and 14 weeks
|
Improvement post treatment
|
2 weeks and 14 weeks
|
|
Improvement post treatment as measured by the Modified Ashworth Scale
Prazo: 2 weeks and 14 weeks
|
Improvement post treatment
|
2 weeks and 14 weeks
|
|
Improvement post treatment as measured by the Motor Activity Log
Prazo: 2 weeks and 14 weeks
|
Improvement post treatment
|
2 weeks and 14 weeks
|
|
Montreal Cognitive Assessment Test
Prazo: 2 weeks and 14 weeks
|
No cognitive deterioration post treatment
|
2 weeks and 14 weeks
|
|
Structural Connectivity as measured by diffusion tensor imaging analysis
Prazo: 2 weeks
|
Improvement post treatment
|
2 weeks
|
|
Functional Connectivity as measured by resting-state functional magnetic imaging analysis
Prazo: 2 weeks
|
Improvement post treatment
|
2 weeks
|
|
Improvement post treatment as measured by the Barthel index
Prazo: 2 week and 14 weeks
|
Improvement post treatment
|
2 week and 14 weeks
|
|
Safety of the intervention as assessed by frequency of adverse events
Prazo: 14 weeks
|
frequency of adverse events in the active and sham arms
|
14 weeks
|
|
Improvement post treatment as measured by Pittsburgh Sleep Quality Index
Prazo: 2 week and 14 weeks
|
Improvement post treatment
|
2 week and 14 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Adriana B Conforto, MD Phd, Hospital Israelita Albert Einstein
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 225014
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Sham tDCS
-
Nova Southeastern UniversitySurgical Specialists of MiamiConcluído
-
Centre Hospitalier Universitaire de NiceRetirado
-
National Cancer Institute (NCI)RecrutamentoNeoplasias | Tumores SólidosEstados Unidos
-
Northwestern UniversityConcluídoNarcolepsia | Narcolepsia Tipo 1 | Narcolepsia Sem Cataplexia | Narcolepsia com Cataplexia | Narcolepsia tipo 2Estados Unidos
-
University of OklahomaVA Office of Research and DevelopmentRescindidoIsquemia Cerebral | Infarto CerebralEstados Unidos
-
University of PennsylvaniaTeleflex; Arrow InternationalConcluídoInsuficiência Renal Crônica Requerendo Hemodiálise | Insuficiência Renal CrônicaEstados Unidos
-
Abant Izzet Baysal UniversityThe Scientific and Technological Research Council of TurkeyRetiradoCâncer de mama | LinfedemaPeru
-
Cairo UniversityConcluído
-
Oulu University HospitalLoisto Terveys, Oulu; Fysios Kastelli, Oulu; Faskia-Markus, OuluInscrevendo-se por conviteDor lombar | Lombalgia RecorrenteFinlândia
-
Otolith LabsConcluído